



Syngene International Limited

Ref: Syn/CS/SE/PR/2020-21/October/69

Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India

T +91 80 6891 8000

F +91 80 6891 8808

CIN: L85110KA1993PLC01493

www.syngeneintl.com

October 21, 2020

To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Press Release in respect of results for the quarter and half year ended September 30, 2020

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed the press release titled **“Syngene reports second quarter revenue from operations at Rs. 519 Cr, up 12% year on year.”**

The above-mentioned press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra

Company Secretary & Compliance Officer

E: priyadarshini.mahapatra@syngeneintl.com

Enclosed: Press Release along with fact sheet

Syngene reports second quarter revenue from operations at Rs. 519 Cr, up 12% year on year

Bengaluru, October 21, 2020:

Syngene International Limited today announced its second quarter results. The Company posted quarterly total revenue of Rs. 533 Cr compared to Rs 485 Cr in the corresponding quarter of last year. EBITDA for the quarter was up 6% to Rs. 169 Cr while PAT was up 2% to Rs. 84 Cr.

Commenting on the results, **Mr. Jonathan Hunt, Managing Director and Chief Executive Officer - Syngene International Limited**, said: *“The second quarter saw a positive return to growth following a muted first quarter that was impacted by COVID-19, with second quarter revenue from operations growing 12% year-on-year and a PAT growth of 2%. This result reflects a robust operating performance as we have adapted to the COVID-19 situation. We are at near normal operating levels with all our scientists working on site with proper protective measures.*

We are happy to continue to support the global health community in the fight against COVID-19 through our dedicated RT PCR testing laboratory, our research efforts and by developing and supplying reagents and oligonucleotides to diagnostic kit manufacturers.

The credit rating upgrade by ICRA is a further affirmation of Syngene’s strong fundamentals and the confidence the market has in our growth story. We expect to sustain our growth through the second half and are making good progress towards achieving our full year guidance.”

EARNINGS RELEASE

Q2 FY 2020-21

Quarterly Financial Highlights (All numbers in INR Cr except Margins)

	Q2 FY21	Q2 FY20	YoY Change (%)
Revenue	533	485	10
Revenue from operations	519	465	12
EBITDA	169	160	6
EBITDA Margin (%)	32	33	
PAT excluding exceptional gain related to insurance claim	84	82	2
PAT Margin (%)	16	17	

H1 FY21 Financial Highlights (All numbers in INR Cr except Margins)

	H1 FY21	H1 FY20	YoY Change (%)
Revenue	970	927	5
Revenue from operations	941	886	6
EBITDA	309	301	3
EBITDA Margin (%)	32	32	
PAT excluding exceptional gain related to insurance claim	142	154	-8
PAT Margin (%)	15	17	

Business Update

Syngene's second quarter performance was primarily driven by good performance in the Discovery Services and Dedicated R&D Centre divisions. After implementing a broad array



EARNINGS RELEASE

Q2 FY 2020-21

of COVID-19 protective and control measures, including regular free testing for all employees working on site, operations have returned to near normal operating levels.

The Company commenced manufacturing of Remdesivir at its manufacturing facility in Bengaluru with initial distribution expected during the third quarter.

Syngene continues to make an active contribution to the fight against COVID-19. In addition to processing COVID-19 tests for hospitals in the Bengaluru region, the Company has tied up with more than 50 organisations in and around Bengaluru to conduct RT-PCR tests for their employees. The Company's IgG based ELISA test kit has received the ICMR and CDSCO approvals and will be launched by HiMedia shortly. This type of kit will be particularly important to measure optimum immune response once vaccine deployment has started. Furthermore, the Company has joined a global industry consortium, led by long-standing research partner, Bristol Myers Squibb, to support research related to COVID-19. The consortium will share relevant expertise and experience to accelerate the understanding of the virus and work towards improving and deploying current assays and new approaches to COVID-19 testing.

In a further boost to the Company's credit rating, ICRA upgraded its credit rating in August from AA to AA+. This is a further affirmation of Syngene's strong fundamentals and robust business model.

Earnings Call

The Company will conduct a 60-minute call at 1.15 pm IST on October 22, 2020 where the senior management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is +91 22 62801279 / +91 22 71158180. Other toll numbers are listed in the conference call invitation which is posted on the Company website www.syngeneintl.com. The operator will provide instructions on asking questions before the start of the call. A replay of this

call will also be available till 29th October, 2020 on +91 22 71945757 / +91 22 66635757, Playback ID: 26414. We will aim to post the transcript of the conference call on the Company website within seven working days of the investor conference call.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's 4200 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife, as well as 1.9 Mn sq ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading edge science as well as multinationals including GSK and Merck KGaA. For more details, visit www.syngeneintl.com.

Contact details

Investor Contact	Media Contact
Krishnan G P: +91 80 6891 9807 M: +919819992927 Fax: +91 80 2852 3423 E: krishnan.g@syngeneintl.com	Sandeep Nair P: +91 80 6891 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: sandeep.nair@syngeneintl.com

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited ("Syngene") and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.

SYNGENE GROUP

FACT SHEET

September - 2020

SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)		(Rs. Crores)	
BALANCE SHEET		30 September 2020	31 March 2020
ASSETS			
Non-current assets			
Property, plant and equipment	1,926	1,877	
Capital work-in-progress	225	234	
Right-of-use assets	117	86	
Investment property	40	36	
Intangible assets	17	21	
Financial assets			
(i) Investments	10	38	
(ii) Derivative assets	41	25	
(iii) Other financial assets	16	15	
Deferred tax assets (net)	101	123	
Income tax assets (net)	76	76	
Other non-current assets	16	19	
Total non-current assets	2,585	2,550	
Current assets			
Inventories	58	25	
Financial assets			
(i) Investments	596	738	
(ii) Trade receivables	265	398	
(iii) Cash and cash equivalents	386	193	
(iv) Bank Balances other than (iii) above	329	89	
(v) Derivative assets	46	19	
(vi) Other financial assets	131	69	
Other current assets	89	82	
Total current assets	1,900	1,613	
Total assets	4,485	4,163	
EQUITY AND LIABILITIES			
Equity			
Equity share capital	400	400	
Other equity	2,061	1,776	
Total equity	2,461	2,176	
LIABILITIES			
Non - current liabilities			
Financial liabilities			
(i) Borrowings	368	-	
(ii) Lease liabilities	114	81	
(iii) Derivative liabilities	58	138	
Provisions	46	41	
Other non-current liabilities	190	188	
Total non-current liabilities	776	448	
Current liabilities			
Financial liabilities			
(i) Borrowings	287	309	
(ii) Lease liabilities	8	6	
(iii) Trade payables	193	222	
(iv) Derivative liabilities	16	55	
(v) Other financial liabilities	467	495	
Provisions	45	42	
Income tax liabilities (net)	13	11	
Other current liabilities	219	399	
Total current liabilities	1,248	1,539	
Total equity and liabilities	4,485	4,163	

SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)
PROFIT AND LOSS STATEMENT

(Rs. Crores, except per share data)

Particulars	Q2 FY 21	Q2 FY 20	Variance
INCOME			
Revenue from operations	519	465	12%
Other income	14	20	-33%
Total Revenue	533	485	10%
EXPENDITURE			
Material and power costs	144	138	4%
Staff costs	161	132	22%
Foreign exchange (net)	(7)	(3)	113%
Other expenses	66	58	12%
Material, power, staff, forex and other expenses	364	325	
EBITDA	169	160	6%
Finance costs	7	8	-21%
Depreciation and amortisation expenses	68	53	31%
PROFIT BEFORE TAX AND EXCEPTIONAL ITEM	94	99	-5%
Tax on above	10	17	
PROFIT AFTER TAX BEFORE EXCEPTIONAL ITEM	84	82	2%
Exceptional item, net of taxes	-	46	
NET PROFIT FOR THE PERIOD	84	128	-34%
EPS - Basic	2.12	3.23	
EPS - Diluted	2.10	3.22	

Note: a) The figures are rounded off to the nearest crore, percentages are based on absolute numbers

SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)
PROFIT AND LOSS STATEMENT

(Rs. Crores, except per share data)

Particulars	Q2 FY 21	Q1 FY 21	Variance
<u>INCOME</u>			
Revenue from operations	519	422	23%
Other income	14	15	-10%
Total Revenue	533	437	22%
<u>EXPENDITURE</u>			
Material and power costs	144	102	41%
Staff costs	161	140	15%
Foreign exchange (net)	(7)	3	-306%
Other expenses	66	52	28%
Material, power, staff, forex and other expenses	364	297	
EBITDA	169	140	21%
Finance costs	7	8	-11%
Depreciation and amortisation expenses	68	66	4%
PROFIT BEFORE TAX	94	66	42%
Tax on above	10	8	
PROFIT AFTER TAX	84	58	45%
EPS - Basic	2.12	1.47	
EPS - Diluted	2.10	1.46	

Note: a) The figures are rounded off to the nearest crore, percentages are based on absolute numbers

SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)**PROFIT & LOSS STATEMENT****(Rs. Crores, except per share data)**

Particulars	H1 FY 21	H1 FY 20	Variance
INCOME			
Revenue from operations	941	886	6%
Other income	29	41	-29%
Total Revenue	970	927	5%
EXPENDITURE			
Material and power costs	245	255	-4%
Staff costs	302	264	14%
Foreign exchange (net)	(4)	(5)	-27%
Other expenses	118	112	6%
Material, power, staff, forex and other expenses	661	626	
EBITDA	309	301	3%
Finance costs	14	15	-10%
Depreciation and amortisation expenses	135	100	35%
PROFIT BEFORE TAX AND EXCEPTIONAL ITEM	160	186	-14%
Tax on above	18	32	
PROFIT AFTER TAX BEFORE EXCEPTIONAL ITEM	142	154	-8%
Exceptional item, net of taxes	-	46	
NET PROFIT FOR THE PERIOD	142	200	-29%
EPS - Basic	3.58	5.04	
EPS - Diluted	3.57	5.03	

Note: a) The figures are rounded off to the nearest crore, percentages are based on absolute numbers